Health Canada sanctioned phase 2 clinical trial of novel cure for C Difficile Infection. C Difficile Infection (CDI) is caused by Clostridioides Difficile bacteria, a gram-positive spore forming pathogen that causes severe diarrhea. ImmuniMed Inc, a Winnipeg based Biopharmaceutical company is the trial sponsor and developer of the novel treatment. Eligible patients will have what is considered mild to moderate C Diff Infection, with associated clinical symptoms. For further information, patients should ask their physician to contact the sponsor or Trial Study Nurse to see if they are eligible to participate. ImmuniMed Inc John Hare, 204-955-8495 Trial Study Nurse Karen Babaian, 204-292-6038